相关实验视频

Updated: Jun 5, 2025

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

对抗耐药结核病活性异化衍生物的膜相互作用研究

Joana F P R Terreiro¹, Joaquim T Marquês¹, Inês Antunes¹

¹Departamento de Química e Bioquímica, Faculdade de Ciências, Centro de Química Estrutural, Institute of Molecular Sciences, Universidade de Lisboa, Campo Grande 1749-016, Portugal.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences

|December 14, 2024

概括

新的抗结核化合物INHC10和N34通过与细菌膜相互作用,显示出对抗耐药结核病的前景. 它们穿透Mycobacterium结核病细胞壁的能力表明了改善治疗的潜力.

科学领域:

生物化学生物化学
药用化学医学化学
分子生物学分子生物学

背景情况:

结核病 (TB) 仍然是一个全球卫生危机,由多药耐药菌株Mycobacterium tuberculosis (Mtb) 加剧.
目前的疗法往往对抗性Mtb菌株无效,需要开发新的抗结核药物.
了解药物膜相互作用对于设计能够克服生物障碍的有效治疗至关重要.

研究的目的:

评估异化 (INH) 和其衍生物 (INHC10,N34,N34red) 与生物膜模型的相互作用.
评估这些化合物透mtb细胞壁的潜力及其对膜性质的影响.
提供对有希望的抗结核候选药物的疗效和低毒性的分子洞察力.

主要方法:

利用生物膜模型研究不同阶段的化合物-脂质相互作用 (凝,液体无序,液体有序/无序).
采用弗斯特的共振能量转移 (FRET) 试验,分析化合物对脂质域组织在模型细胞膜中的影响.
评估化合物的脂性,与人血清白蛋白的相互作用,以及与Mtb.相比的体外选择性指数.

主要成果:

INHC10和N34在体外表现出良好的选择性和脂性,表明了治疗潜力.
所有化合物,除N34红色改变的乙链包装在脂质双层;INHC10显著扰乱液体混乱的膜.
化合物 (INH除外) 降低了膜双极电位,N34red显示出极大的影响.
FRET测定没有显著影响脂质域大小或异质膜中的组织.
插入凝相二层表明,可能会透硬的mtb细胞壁.

结论:

由于INHC10和N34的膜相互作用形状,它们对开发新的抗结核药物具有有前途的特性.
这些化合物与细菌膜相互作用和潜在地透的能力,有助于它们对抗耐药MTB的有效性.
了解这些分子相互作用为人类细胞系中观察到的低毒性和改善对抗耐药Mtb菌株的活性提供了基础.

关键词:

抗结核化合物是一种抗结核化合物.药物 - 膜相互作用费特 (FRET) 是一个货运运输公司.光光谱学是一种光谱学.脂质漂泊船是指脂质漂泊船.多种药物耐药性结核病

更多相关视频

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

相关概念视频

Pulmonary Tuberculosis V

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...

Combined Effects of Drugs: Synergism

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...

Structure-Activity Relationships and Drug Design

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...